Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6272688 | 0.94 | ALDH1A1 (0.48) | NPC1RAB9APOLBALDH1A1LMNA | |
| SCHEMBL6266719 | 0.89 | ALDH1A1 (0.45) | NPC1RAB9APOLBALDH1A1LMNA | |
| SCHEMBL6271800 | 0.89 | GLA (0.46) | NPC1RAB9APOLBALDH1A1LMNA | |
| SCHEMBL6265407 | 0.89 | TP53 (0.48) | RAB9APOLBALDH1A1MAPTNR4A2 | |
| SCHEMBL6270830 | 0.88 | MAPT (0.47) | POLBALDH1A1LMNAMAPTTP53 | |
| SCHEMBL6269203 | 0.88 | ALDH1A1 (0.58) | POLBALDH1A1LMNAMAPTTP53 | |
| SCHEMBL9031178 | 0.88 | ALDH1A1 (0.53) | RAB9APOLBALDH1A1LMNAMAPT | |
| SCHEMBL6267362 | 0.88 | LMNA (0.55) | NPC1RAB9APOLBALDH1A1LMNA | |
| SCHEMBL6272305 | 0.88 | KMT2A (0.53) | NPC1RAB9APOLBALDH1A1LMNA | |
| SCHEMBL1083593 | 0.88 | POLB (0.54) | NPC1RAB9APOLBADORA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3275666-A | — | — | None | — | — | JP | disclosed |
| EP-2268641-B1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT LTD (IN) | 2014-09-03 | — | — | EP | disclosed |
| EP-2268641-B1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT LTD (IN) | 2014-09-03 | — | — | EP | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| US-8252797-B2 | Heterocyclic compounds as adenosine receptor antagonist | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2012-08-28 | — | — | US | disclosed |
| EP-2268641-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | Advinus Therapeutics Pvt. Ltd. (IN) | 2011-01-05 | — | — | EP | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD. (IN) | 2009-12-03 | — | — | US | disclosed |
| WO-2009118759-A2 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADVINUS THERAPEUTICS PVT. LTD., (IN) | 2009-10-01 | — | — | WO | disclosed |
| EP-1000620-B1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6166036-A | Lp(a)-lowering agent and apolipoprotein (a) formation suppressing agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-1000620-A1 | Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| EP-0393607-B1 | Phenylcarboxylic acid derivatives having a hetero ring | OTSUKA PHARMA CO LTD (JP) | 1996-02-21 | — | — | EP | disclosed |
| US-5145865-A | Fatty acid, cholesterol synthesis inhibitors; enzyme inhibitors; antilipemic agents | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1992-09-08 | — | — | US | disclosed |
| JP-H03275666-A | PHENYLCARBOXYLIC ACID DERIVATIVE HAVING HETERO RING | OTSUKA PHARMACEUT CO LTD | 1991-12-06 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298744-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA1 | NPC1 2281/4885RAB9A 1867/4885POLB 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.